Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

This study has been terminated.
(Based on futility analysis showing <30% chance of meeting primary endpoint.)
Sponsor:
Information provided by:
Cell Genesys
ClinicalTrials.gov Identifier:
NCT00089856
First received: August 16, 2004
Last updated: November 3, 2008
Last verified: November 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2008
  Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
No publications provided by Cell Genesys

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):